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BACKGROUND: In stable coronary artery disease, medications are used for 2 purposes: cardiovascular risk reduction and 
symptom improvement. In clinical trials and clinical practice, medication use is often not optimal. The ORBITA (Objective 
Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) trial was the first placebo-
controlled trial of percutaneous coronary intervention. A key component of the ORBITA trial design was the inclusion of a 
medical optimization phase, aimed at ensuring that all patients were treated with guideline-directed truly optimal medical 
therapy. In this study, we report the medical therapy that was achieved.
METHODS AND RESULTS: After enrollment into the ORBITA trial, all 200 patients entered a 6-week period of intensive medical 
therapy optimization, with initiation and uptitration of risk reduction and antianginal therapy. At the prerandomization stage, 
the median number of antianginals established was 3 (interquartile range, 2–4). A total of 195 patients (97.5%) reached the 
prespecified target of ≥2 antianginals; 136 (68.0%) did not stop any antianginals because of adverse effects, and the median 
number of antianginals stopped for adverse effects per patient was 0 (interquartile range, 0–1). Amlodipine and bisoprolol were 
well tolerated (stopped for adverse effects in 4/175 [2.3%] and 9/167 [5.4%], respectively). Ranolazine and ivabradine were also 
well tolerated (stopped for adverse effects in 1/20 [5.0%] and 1/18 [5.6%], respectively). Isosorbide mononitrate and nicorandil 
were stopped for adverse effects in 36 of 172 (20.9%) and 32 of 141 (22.7%) of patients, respectively. Statins were well toler-
ated and taken by 191 of 200 (95.5%) patients.
CONCLUSIONS: In the 12-week ORBITA trial period, medical therapy was successfully optimized and well tolerated, with few 
drug adverse effects leading to therapy cessation. Truly optimal medical therapy can be achieved in clinical trials, and translat-
ing this into longer-term clinical practice should be a focus of future study.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT02062593.
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The treatment aims for patients with stable coronary artery disease (CAD) are to reduce the risk of fu-ture cardiovascular events and to improve angina 
symptoms.1 Reducing the risk of future cardiovascu-
lar events is achieved by slowing disease progression, 
reducing plaque instability, and reducing thrombus 
aggregation. This is achieved with lifestyle modifica-
tion, high-intensity statin therapy, and antiplatelets.2 
Large randomized controlled trials in stable CAD have 
demonstrated that percutaneous coronary intervention 
(PCI) does not confer a survival benefit or a reduced 
risk of myocardial infarction, when added to optimal 
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medical therapy.3,4 In the ISCHEMIA (International 
Study of Comparative Health Effectiveness With 
Medical and Invasive Approaches) trial, even in the 
context of moderate or severe ischemia, PCI did not 
prevent myocardial infarction or death.5
The second aim of treatment is symptom relief. 
National and international guidelines recommend ini-
tial use of antianginal medications, which can be used 
in combination to reduce symptoms. If a patient’s 
angina is not well controlled with the use of short-act-
ing nitrates alone, recommended first-line therapy is 
either a β blocker or a calcium channel antagonist. 
Second- and third-line agents, including long-act-
ing nitrates, nicorandil, ivabradine, and ranolazine, 
should be chosen according to comorbidities, contra-
indications, patient preference, and medication cost. 
Revascularization is considered for patients who re-
main symptomatic despite treatment with at least 2 an-
tianginal agents or are intolerant of medical therapy.6,7
Initiating and uptitrating antianginal therapy can 
present a challenge in clinical practice for a variety of 
reasons. Engaging in an intensive process of antianginal 
medication introduction and uptitration may be seen as 
more time-consuming than an upfront PCI procedure. 
Clinician and patient concern about polypharmacy can 
mean that antianginals are not introduced or uptitrated. 
Adverse effects may result in poor medication per-
sistence and adherence, leading to patients not consis-
tently taking enough antianginal therapy to effectively 
treat their symptoms.8 Medical therapy may also not be 
optimized because of discordance between clinician 
and patient estimation of angina.9
In the ORBITA (Objective Randomised Blinded 
Investigation With Optimal Medical Therapy of 
Angioplasty in Stable Angina) trial, patients with an-
gina and single-vessel severe coronary stenosis un-
derwent a prespecified period of antianginal therapy 
uptitration. The medication optimization phase was 
intensive to achieve good levels of medical therapy in 
only 6 weeks.10 In this article, we describe the medical 
therapy that was achieved during the medical optimi-
zation and follow-up phases. We report which drugs 
were best tolerated, the adverse effects experienced, 
and the low-density lipoprotein and blood pressure 
achieved.
METHODS
The data, analytical methods, and study materials 
will not be made available to other researchers for 
the purposes of reproducing the results or replicating 
the procedure. The London Central Research Ethics 
Committee (reference 13/LO/1340) approved the 
study, and written consent was obtained from all pa-
tients before enrollment.
Study Design
The methods of the ORBITA trial have been reported 
previously.10 In brief, patients were eligible for recruit-
ment if they had symptoms of angina and ≥1 signifi-
cant angiographic stenosis (≥70%) in a single coronary 
artery. Medical therapy and symptoms at enrollment 
were recorded. Study participants subsequently en-
tered a 6-week medical optimization phase.
CLINICAL PERSPECTIVE
What Is New?
• In the ORBITA (Objective Randomised Blinded 
Investigation With Optimal Medical Therapy 
of Angioplasty in Stable Angina) trial, the first 
placebo-controlled trial of percutaneous coro-
nary intervention in stable angina, patients un-
derwent a 6-week medical optimization period 
before randomization to percutaneous coronary 
intervention or placebo.
• We demonstrate that in a clinical trial setting, 
truly optimal medical therapy can be success-
fully established and well tolerated, with 97.5% 
of patients taking ≥2 antianginal medications at 
6 weeks.
What Are the Clinical Implications?
• It is possible to attain truly optimum medi-
cal therapy within trials of stable angina. This 
level of therapy may also translate into clinical 
practice.
• The impact of antianginal optimization on the 
placebo-controlled effect of percutaneous cor-
onary intervention is not known; this should be 
the subject of future research.
Nonstandard Abbreviations and Acronyms
ACME  Angioplasty Compared to 
Medicine
COURAGE  Clinical Outcomes Utilizing 
Revascularization and Aggressive 
Drug Evaluation
FAME 2  Fractional Flow Reserve Versus 
Angiography for Multivessel 
Evaluation 2
ISCHEMIA  International Study of Comparative 
Health Effectiveness With Medical 
and Invasive Approaches
ORBITA  Objective Randomised Blinded 
Investigation With Optimal Medical 
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Participants then underwent prerandomization 
assessment with angina severity quantification using 
Canadian Cardiovascular Society class and Seattle 
Angina Questionnaire score, cardiopulmonary exercise 
testing, and dobutamine stress echocardiography. 
They then attended for the randomization visit, where 
they had measurement of fasting lipid profile, including 
low-density lipoprotein. After being sedated to a deep 
level of conscious sedation, patients were randomized 
to PCI or a placebo procedure.
After a 6-week blinded follow-up phase, patients 
returned for repeated symptom assessment, cardio-
pulmonary exercise testing, and dobutamine stress 
echocardiography. They were then unblinded and re-
turned to routine care.
Daily home monitoring of pulse and blood pressure 
was performed throughout using equipment provided 
by the trial team (Omron M6 monitor; Omron, Kyoto, 
Japan).
Medical Therapy
The 6-week medical optimization phase consisted of 
telephone consultations 1 to 3 times per week with a 
consultant cardiologist, supported by regular home 
blood pressure and heart rate monitoring, to introduce 
and uptitrate risk reduction and antianginal medica-
tion. Medication changes were made by a consultant 
cardiologist in consultation with study participants. 
Medication choice was based on national guidelines 
and individual patient considerations.
Patients were started on aspirin and a statin, aim-
ing to achieve a dose equivalent to 40 mg atorvastatin. 
Antianginal therapy was guideline directed, aiming to 
establish study participants on ≥2 of the following an-
tianginal drugs (or equivalent): bisoprolol, ≥5 mg once a 
day; amlodipine, ≥5 mg once a day; isosorbide mono-
nitrate, 25 mg once a day; nicorandil, 10 mg twice a 
day; ivabradine, 7.5 mg twice a day; and ranolazine, 
500 mg twice a day (Table 1). The antianginal esca-
lation strategy is shown in Figure 1.11 A second anti-
platelet agent was started before the randomization 
procedure.
The ORBITA trial was not designed to detect differ-
ences in cardiovascular events. However, to ensure pa-
tients received optimal risk reduction therapy, targets 
of a low-density lipoprotein cholesterol of <1.8 mmol/L 
and a systolic blood pressure of <140  mm  Hg were 
used. These were assessed at prerandomization.
An online case reporting form was completed by the 
study team, which detailed medication initiation, ad-
verse effects, and reasons for medication change and 
cessation. Most patients were prescribed short-acting 
nitrates; these were used at the patient’s discretion. 
Use of short-acting nitrates was not recorded.
Statistical Analysis
Normally distributed data are presented as mean and 
SD. Nonnormally distributed data are presented as 
median and interquartile range. The association be-
tween the number of antianginal medications used 
and placebo-controlled efficacy of PCI was assessed 
using regression modeling. Models included the pre-
randomization end point value, the number of antiangi-
nal medications tolerated, and the randomization arm. 
The number of antianginal medications was allowed to 
interact with the randomization arm. Restricted cubic 
splines (with 3 knots) were placed on the number of 
antianginal medications and prerandomization exer-
cise time. Least square models were used for exercise 
time, proportional odds model was used for Canadian 
Cardiovascular Society class and Seattle Angina 
Questionnaire angina frequency, and logistic model 
was used for freedom from angina. Analyses were per-
formed using the open-source statistical environment 
R (version 4.0.2) with the “rms” regression modeling 
package.12
Table 1. Target Doses for Medical Therapy in the ORBITA Trial
Antianginal Therapy (≥2 Antianginals From the Following) Dose
Bisoprolol (or equivalent β blocker) ≥5 mg once per day
Amlodipine (or equivalent calcium channel antagonist) ≥5 mg once per day
Isosorbide mononitrate (or equivalent long-acting oral nitrate) 25 mg once per day
Nicorandil 10 mg twice per day
Ivabradine 7.5 mg twice per day
Ranolazine 500 mg twice per day
Risk reduction therapy Dose
Aspirin 75 mg once per day
Clopidogrel (or equivalent antiplatelet therapy) 75 mg once per day
Atorvastatin ≥40 mg once per day
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RESULTS
Medication use and adverse effect data were avail-
able for all 200 ORBITA trial patients. Of the original 
230 participants who entered the medical optimiza-
tion phase, 30 left the study before randomization; 5 
of these patients left because of medication adverse 
effects.
Antianginal Therapy
The median number of antianginals started (or contin-
ued after enrollment) was 4 (interquartile range, 3–4). 
The median number of antianginals established (taken 
without stopping the drug for any reason) for each 
patient was 3 (interquartile range, 2–4). A total of 146 
(73.0%) patients were established on ≥3 antianginals; 
195 (97.5%) patients reached the trial target of ≥2 an-
tianginals (Table 2). The mean antianginal drugs taken 
by the end of each week is shown in Figure  2. The 
percentage of patients on 0 to 5 antianginal drugs by 
the end of each week is shown in Figure S1.
The median number of antianginals stopped per 
patient was 0 (interquartile range, 0–1). A total of 136 
patients (68.0%) did not stop any antianginals be-
cause of adverse effects, 44 (22.0%) patients stopped 
1, 19 (9.5%) patients stopped 2, and 1 (0.5%) patient 
stopped 3.
Fourteen different antianginal drugs were taken by 
patients in the ORBITA trial. Where <15 patients took 
a drug, use and adverse effects are not individually re-
ported. Table 3 shows individual antianginal drug use 
and adverse effect data. Most patients were able to tol-
erate a high level of antianginal therapy. Calcium chan-
nel antagonists were started in 198 (99.0%) patients 
and were still being taken at follow-up in 182 (91.9%). 
Figure 1. The antianginal decision-making process that was used in the ORBITA (Objective 
Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) 
trial, based on the National Institute of Health and Care Excellence and European Society of 
Cardiology guidelines.11
Ca indicates calcium; GTN, glyceryl trinitrate; and MI, myocardial infarction.
Table 2. Summary of Antianginal Therapy in the ORBITA 
Trial
Antianginal Therapy Median (IQR)
Antianginals started or continued at 
enrollment
4 (3–4)
Antianginals successfully established 3 (2–4)
Antianginals stopped 0 (0–1)
IQR indicates interquartile range; and ORBITA, Objective Randomised 
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Of the 175 (87.5%) patients started on amlodipine, 133 
(76.0%) reached the target dose and 4 (2.3%) stopped 
because of adverse effects. β Blockers were started 
in 183 (91.5%) patients and were still being taken at 
follow-up in 164 (89.6%). Of the 167 patients started 
on bisoprolol, 91 (54.5%) reached the target dose and 
9 (5.4%) stopped for adverse effects.
Isosorbide mononitrate was started in 172 (86.0%) 
patients, 127 (73.8%) reached the target dose, and 36 
(20.9%) stopped for adverse effects; isosorbide mono-
nitrate was still being taken at follow-up in 133 (77.3%) of 
patients. Nicorandil was started in 141 (70.5%) patients, 
102 (72.3%) reached the target dose, and 32 (22.7%) 
stopped for adverse effects; nicorandil was still being 
taken at follow-up in 106 (75.2%) of patients. The most 
common adverse effect experienced by patients taking 
isosorbide mononitrate and nicorandil was headache.
Ivabradine was started in 18 (9.0%) patients, 8 
(44.4%) reached the target dose, and 1 (5.6%) stopped 
for adverse effects. Three additional patients were 
started on ivabradine during the follow-up phase. 
Ranolazine was started in 20 (10.0%) patients, 18 
(90.0%) reached the target dose, and 1 (5.0%) stopped 
for adverse effects; ranolazine was still being taken at 
follow-up in 19 (95%) of patients.
Figure 3 shows the proportion of patients for each 
drug class started on therapy, reaching the target 
dose, and stopping for adverse effects. At follow-up, 
the medication use for all drugs and classes was simi-
lar to the prerandomization time point.
The number of antianginal agents was not associated 
with the placebo-controlled efficacy of PCI on freedom 
from angina (P=0.556; Figure  4). There was similarly 
no association with change in exercise time (P=0.251), 
Canadian Cardiovascular Society class (P=0.765), 
or Seattle Angina Questionnaire angina frequency 
(P=0.333) (Figures S2–S4). The full logistic regression 
output is included in the supplemental material, along 
with Canadian Cardiovascular Society class and Seattle 
Angina Questionnaire angina frequency at enrollment, 
prerandomization, and follow-up (Tables S1–S3).
Statin and Dual-Antiplatelet Therapy
Table  4 shows statin therapy. A total of 196 (98.0%) 
patients were started on at least 1 statin agent; the 
remaining 4 (2.0%) had previous documented intol-
erance. At randomization, 191 (95.5%) patients were 
taking a statin: 174 (87.0%) on atorvastatin, 16 (8%) on 
rosuvastatin, and 1 (0.5%) on simvastatin. Of the 196 
patients started on a statin, 8 (4.1%) experienced ad-
verse effects leading to change of agent or statin ces-
sation. Of the 181 patients started on atorvastatin, 171 
(94.5%) achieved the target dose and 4 (2.2%) stopped 
because of adverse effects. The most common ad-
verse effect was muscle pain (n=3 [1.7%]).
All 200 patients were started on at least one an-
tiplatelet agent, with 194 (97.0%) on dual-antiplatelet 
therapy. Adverse effects leading to antiplatelet cessa-
tion were uncommon, with only 1 patient temporarily 
stopping aspirin for upper gastrointestinal bleeding 
and 1 stopping ticagrelor for shortness of breath. The 
antiplatelet and statin data are shown in Figure S5.
At prerandomization, mean low-density lipopro-
tein was 1.84±0.74 mmol/L, with 102 (51.0%) patients 
reaching target. Mean systolic blood pressure was 
125.6±16.9 mm Hg, with 159 (79.5%) patients reaching 
target. The blood pressure and heart rate at enrollment, 
prerandomization, and follow-up are reproduced from 
a previous publication in Table S4.10
DISCUSSION
In this analysis of medical therapy in the ORBITA trial, 
we have shown that, within a 12-week trial period, it 
is possible to achieve guideline-directed truly optimal 
medical therapy. Antianginal therapy was initiated and 
uptitrated to effective doses in the majority. Amlodipine, 
bisoprolol, ranolazine, and ivabradine were well toler-
ated, whereas isosorbide mononitrate and nicorandil 
were associated with more adverse effects than other 
antianginal agents. Statins were well tolerated, causing 
adverse effects in only a small minority of patients.
Antianginal Therapy in Trials of PCI
The first trial of PCI for angina in the balloon angi-
oplasty era, the ACME (Angioplasty Compared to 
Medicine) trial, used a “stepped-care approach” with 
medical therapy in the control arm. Relatively low lev-
els of medical therapy were achieved at 6 months, 
with 59%, 50%, and 71% of patients taking nitrates, 
Figure 2. Antianginal drugs per patient from enrollment to 
follow-up.
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β blockers, and calcium channel antagonists, re-
spectively, in the control arm, and much lower levels 
in the treatment arm.13 Multiple trials in stable CAD 
followed; however, the importance of attempting to 
attain truly optimal medical therapy was emphasized 
and integrated into trial design by the COURAGE 
(Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation) trial.3 At randomization, 
67.4%, 86.8%, and 41.4% of patients were on a ni-
trate, β blocker, and calcium channel antagonist, re-
spectively. Medical therapy was more modest in the 
subsequent FAME 2 (Fractional Flow Reserve Versus 
Angiography for Multivessel Evaluation 2) trial, with 
76.7% on β blockers and only 23.1% on calcium 
channel antagonists. Nitrate use was unreported. 
More recently, the ISCHEMIA trial was designed to 
compare an initial invasive or conservative strat-
egy, in patients with moderate to severe ischemia. 
Despite the complexity of medication optimization in 
this large, multicenter, international trial, a great deal 
of effort was invested in trying to attain optimal medi-
cal therapy.14 There was a high level of β-blocker use, 
81.0%, with lower levels of calcium channel antago-
nist use, 30.2%, at enrollment,14 and similar propor-
tions at follow-up.5
This analysis has demonstrated that the average 
ORBITA trial patient was on a much higher level of 
antianginal therapy than in routine clinical practice 
or other trials of PCI.3–5,13 This may be for a variety 
of reasons. First, for optimal medical therapy to be 
achieved, it must be imbedded in the trial design 
with strict protocols and plans for medication intro-
duction, response evaluation, and changes, where 
necessary. Second, teams must be well trained 
and patients must be willing to accept the medi-
cation protocol. However, it must be remembered 
that the length of a clinical trial period may have 
an impact on persistence and adherence to optimal 
medical therapy. Higher levels of therapy may be 
easier to maintain over a shorter clinical trial pe-
riod, such as the 12 weeks of the ORBITA trial. This 
must be taken into consideration when comparing 
clinical trials and considering translation into clinical 
practice.
The incremental efficacy of PCI in a clinical trial 
may depend on the level of background medical 
therapy that is established.1 For a subjective end 
point, such as symptom relief, the effect of any treat-
ment will consist of a combination of both a physical 
and a placebo component.15 All unblinded trials of 
revascularization versus a conservative approach in 
stable CAD showed improvement in symptoms of an-
gina.5,13,16,17 Some of this treatment effect may have 
been caused by placebo, but it is also possible that 
the benefit of PCI is increased if introduced on lower 
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therapy in the ORBITA trial may have resulted in a 
reduction in the potential incremental impact of PCI 
on the physical component of the treatment effect. 
Perhaps as a result, PCI only demonstrated mini-
mal placebo-controlled symptom efficacy on one 
secondary end point of patient-reported freedom 
from angina and has small but nonnegligible short- 
and long-term adverse effects.18
This phenomenon is analogous to the data from 
trials of renal denervation. In the early unblinded 
Figure 3. Antianginal medication: number of patients established on each medication class, 
achieving target dose and stopping for adverse effects.
ISMN indicates isosorbide mononitrate.
Figure 4. Logistic regression showing the association between the number of prescribed 
antianginal therapies and log odds of freedom from angina.
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renal denervation trials, with patients on modest 
levels of antihypertensive therapy, the effect of renal 
denervation on blood pressure reduction was pro-
nounced.19,20 Later, the first placebo-controlled trial 
of denervation on a background of intense antihyper-
tensive therapy showed a much smaller and not sta-
tistically significant effect size.21 More recently, renal 
denervation has been tested in patients off antihy-
pertensive therapy, showing a larger effect size of the 
interventional therapy.22 These data suggest that the 
effect size of an intervention can be magnified by in-
troducing the intervention to patients on lower levels 
of medical therapy, thereby increasing the physical 
component of its treatment effect.
Alternatively, it may be that if a patient with stable 
angina has a good response to antianginal medica-
tion, we can be certain that the symptoms are re-
lated to CAD. If, however, angina does not improve 
despite introduction of multiple antianginal agents, it 
may be more likely that the symptoms are not car-
diac. Therefore, perhaps patients with the best re-
sponse to antianginal therapy can be expected to 
have the greatest symptomatic improvement with 
revascularization.
Although, in this analysis of the ORBITA trial, 
there was no association between the number of 
antianginal medications at prerandomization and 
the placebo-controlled efficacy of PCI, this may be 
because the cohort was on high levels of therapy 
(97.5% of patients on ≥2 antianginal medications by 
randomization). Therefore, there may have been in-
sufficient variation in antianginal medication across 
the trial population to adequately test this possible 
association.
Clinical Implications
In clinical practice, patients are often not established 
on adequate medical therapy before being referred 
for PCI. In a UK study, only 32% of patients were on 2 
antianginal drugs before being referred for PCI, with 
9% of patients on no antianginal drugs at all.8 This 
may in part be because of concern about the toler-
ability of the regimen, polypharmacy, and possible 
adverse effects. The process of introduction and up-
titration of antianginal therapy may be seen as labor 
intensive and unrealistic in current clinical practice. 
In addition, patients and physicians may consider an 
upfront PCI procedure to be simpler, more readily ac-
cessible, and preferable. We have demonstrated that, 
in the context of a 12-week clinical trial, antianginal 
therapy is well tolerated in the majority and that ad-
verse effects leading to drug stoppages are rare. In 
particular, amlodipine and bisoprolol were well toler-
ated, with the highest rates of adverse effects seen 
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the results of the ISCHEMIA trial, clinicians should be 
confident to prescribe and uptitrate antianginal ther-
apy in the knowledge they are not denying their pa-
tient a procedure with prognostic benefit. However, 
in clinical practice, patients may not want to take ≥3 
antianginal drugs long-term, preferring to pursue PCI. 
The ORBITA-2 trial will further address this question 
by investigating the placebo-controlled efficacy of 
PCI in patients taking real-world antianginal therapy.23
Study Limitations
Within the ORBITA trial, patient-physician interaction 
was more intense than would be realistic in routine 
clinical practice. With 2 to 3 telephone consultations 
with a physician per week, it is possible that patients 
may have been more likely to tolerate higher degrees 
of medical therapy than would be achievable in rou-
tine clinical practice. However, the frequency of inter-
action was driven by the necessity to complete the 
medical optimization phase within 6 weeks to ensure 
that the trial was feasible, ethical, and acceptable. 
In routine clinical practice, consultations could be 
distributed over a longer time to achieve the same 
effect.
This analysis of the ORBITA trial demonstrates the 
feasibility of rapidly uptitrating antianginal therapy in 
a clinical study setting with a relatively short duration 
of follow-up. Of 230 patients enrolled into the trial, 5 
left before randomization because of medication ad-
verse effects. It is possible that the 200 randomized 
patients may have been more prepared to undergo 
the intensive study regimen than the wider clinical 
population. High levels of antianginal drug therapy 
may be less tolerable over a longer period, with 
poorer persistence and adherence in longer-term 
clinical trials and outside of the setting of clinical 
research.
Patients and physicians were not blinded to the 
medications used in the ORBITA trial. This could have 
influenced the unblinded adverse effect reporting. As 
a UK-based clinical trial, within the National Health 
Service, patients did not need to pay for medication. 
This will not be the case in all healthcare systems and 
may limit the international applicability of these results. 
Also, nicorandil and ivabradine are not licensed as an-
tianginal therapies in the United States.
CONCLUSIONS
The ORBITA trial shows that optimal medical therapy 
with guideline-directed antianginals, statins, and dual 
antiplatelet therapy is achievable and well tolerated by 
most patients in a 12-week trial period. With protocol-
ized medication initiation and uptitration, it is possible 
to achieve truly optimal medical therapy. Future studies 
are required to assess the efficacy of this protocol in 
longer-term clinical practice.
ARTICLE INFORMATION
Received June 23, 2020; accepted December 16, 2020.
Affiliations
From the National Heart and Lung Institute, Imperial College London, 
London, UK (M.F., C.A.R., M.S.-S., H.S., J.H., A.N.N., R.P., I.S.M., S.N., 
S.S., D.P.F., R.A.-L.); Imperial College Healthcare NHS Trust, London, UK 
(M.F., C.A.R., M.S.-S., S.G., H.S., J.H., A.N.N., R.P., I.S.M., S.N., S.S., D.P.F., 
R.A.-L.); Essex Cardiothoracic Centre, Basildon, UK (T.R.K., J.R.D., K.H.T.); 
Anglia Ruskin School of Medicine, Chelmsford, UK (T.R.K., J.R.D.); East 
Sussex Healthcare NHS Trust, Hastings, UK (R.G.); Royal Bournemouth and 
Christchurch NHS Trust, Bournemouth, UK (P.O.);  and University Hospital of 
Wales, Cardiff, UK (A.S.S.).
Acknowledgments
We thank all participants and their families for their dedication to this 
research. We thank the research and administrative teams at Imperial 
College Healthcare NHS Trust, Essex Cardiothoracic Centre, East Sussex 
Healthcare NHS Trust, Royal Devon and Exeter NHS Trust, and Royal 
Bournemouth and Christchurch NHS Trust for their dedication and support.
Sources of Funding
The ORBITA (Objective Randomised Blinded Investigation With Optimal 
Medical Therapy of Angioplasty in Stable Angina) trial was an investigator-
led trial sponsored by Imperial College London. We acknowledge the sup-
port of the National Institute for Health Research (NIHR) Clinical Research 
Network, NIHR Imperial Biomedical Research Centre, Foundation for 
Circulatory Health, Imperial College Healthcare Charity, Philips Volcano, 
and The British Heart Foundation Centre of Research Excellence at 
Imperial.
Disclosures
Dr Sharp is a consultant for Philips Volcano. Drs Sen, Petraco, and Nijjer have 
received speaker’s honoraria from Philips Volcano. Dr Al-Lamee has received 
speaker’s honoraria from Philips Volcano and Menarini Pharmaceuticals. Dr 
Keeble has received research grants from Philips Volcano. The remaining 





 1. Rajkumar CA, Foley M, Al-Lamee R. The Goldilocks Guide to Getting 
Medical Therapy “Just Right”: insights from the ISCHEMIA Trial. Circ 
Cardiovasc Qual Outcomes. 2019;12:e006265. DOI: 10.1161/CIRCO 
UTCOM ES.119.006265.
 2. Randomised trial of cholesterol lowering in 4444 patients with coro-
nary heart disease: the Scandinavian Simvastatin Survival Study (4S). 
Lancet. 1994;344:1383–1389.DOI: 10.1016/S0140 -6736(94)90566 -5.
 3. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, 
Knudtson M, Dada M, Casperson P, Harris CL, et al. Optimal medical 
therapy with or without PCI for stable coronary disease. N Engl J Med. 
2007;356:1503–1516.DOI: 10.1056/NEJMo a070829.
 4. De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth 
Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, et al. Fractional 
flow reserve-guided PCI versus medical therapy in stable coronary 
disease. N Engl J Med. 2012;367:991–1001.DOI: 10.1056/NEJMo 
a1205361.
 5. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, 
Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, et 
al. Initial invasive or conservative strategy for stable coronary disease. N 
Engl J Med. 2020;382:1395–1407.DOI: 10.1056/NEJMo a1915922.
 6. National Institute for Health and Care Excellence (NICE). Management 
of stable angina. NICE Clinical Guidance CG126. 2016. Available at: 




 http://ahajournals.org by on January 28, 2021
J Am Heart Assoc. 2021;10:e017381. DOI: 10.1161/JAHA.120.017381 10
Foley et al Optimal Medical Therapy in ORBITA
 7. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-
Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al. 2019 ESC 
guidelines for the diagnosis and management of chronic coronary syn-
dromes. Eur Heart J. 2020;41:407–477.DOI: 10.1093/eurhe artj/ehz425.
 8. Elder DHJ, Pauriah M, Lang CC, Shand J, Menown IBA, Sin B, Gupta S, 
Duckett SG, Foster W, Zachariah D, et al. Is there a Failure to Optimize 
theRapy in anGina pEcToris (FORGET) study? QJM. 2010;103:305–310.
DOI: 10.1093/qjmed/ hcq011.
 9. Shafiq A, Arnold SV, Gosch K, Kureshi F, Breeding T, Jones PG, 
Beltrame J, Spertus J. Patient and physician discordance in reporting 
symptoms of angina among stable coronary artery disease patients: 
insights from the Angina Prevalence and Provider Evaluation of Angina 
Relief (APPEAR) study. Am Heart J. 2016;175:94–100.DOI: 10.1016/j.
ahj.2016.02.015.
 10. Al-Lamee R, Thompson D, Dehbi H-M, Sen S, Tang K, Davies J, 
Keeble T, Mielewczik M, Kaprielian R, Malik IS, et al. Percutaneous 
coronary intervention in stable angina (ORBITA): a double-blind, ran-
domised controlled trial. Lancet. 2018;391:31–40.DOI: 10.1016/S0140 
-6736(17)32714 -9.
 11. Al-Lamee R, Davies J, Malik IS. What is the role of coronary angioplasty 
and stenting in stable angina? BMJ. 2016;352:i205. DOI: 10.1136/bmj.i205
 12. Frank E H Jr. RMS: regression modeling strategies. 2020. Available 
at: https://CRAN.R-proje ct.org/packa ge=rms. Accessed January 10, 
2020.
 13. Parisi A, Folland E, Hartigan P. A comparison of angioplasty with medi-
cal therapy in the treatment of single-vessel coronary artery disease. N 
Engl J Med. 1992;326:10–16.DOI: 10.1056/NEJM1 99201 02326 0102.
 14. Newman JD, Alexander KP, Gu X, O’Brien SM, Boden WE, Govindan SC, 
Senior R, Moorthy N, Rezende PC, Demkow M, et al. Baseline predictors of 
low-density lipoprotein cholesterol and systolic blood pressure goal attain-
ment after 1 year in the ISCHEMIA trial. Circ Cardiovasc Qual Outcomes. 
2019;12:e006002. DOI: 10.1161/CIRCO UTCOM ES.119.006002.
 15. Ernst E, Resch KL. Concept of true and perceived placebo effects. 
BMJ. 1995;311:551–553. 10.1136/bmj.311.7004.551.
 16. Ilsley C, Farrel T, Paul V, Knight R, Brooks N, Bennett D, Bray C, Levy 
R, Ward C, Coppinger T, et al. Coronary angioplasty versus medical 
therapy for angina: the second Randomised Intervention Treatment of 
Angina (RITA-2) trial. Lancet. 1997;350:461–468.
 17. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz 
C, Zhang W, Hartigan PM, Lewis C, Veledar E, et al. Effect of PCI on 
quality of life in patients with stable coronary disease. N Engl J Med. 
2008;359:677–687.DOI: 10.1056/NEJMo a072771.
 18. Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi H-M, 
Sen S, Nijjer S, Petraco R, Davies J, Keeble T, et al. Fractional flow 
reserve and instantaneous wave-free ratio as predictors of the place-
bo-controlled response to percutaneous coronary intervention in stable 
single-vessel coronary artery disease: physiology-stratified analysis of 
ORBITA. Circulation. 2018;138:1780–1792.DOI: 10.1161/CIRCU LATIO 
NAHA.118.033801.
 19. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, 
Kapelak B, Walton A, Sievert H, Thambar S, et al. Catheter-based renal 
sympathetic denervation for resistant hypertension: a multicentre safety 
and proof-of-principle cohort study. Lancet. 2009;373:1275–1281.DOI: 
10.1016/S0140 -6736(09)60566 -3.
 20. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. 
Renal sympathetic denervation in patients with treatment-resistant hy-
pertension (The Symplicity HTN-2 Trial): a randomised controlled trial. 
Lancet. 2010;376:1903–1909.
 21. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen 
BT, Leon MB, Liu M, Mauri L, Negoita M, et al. A controlled trial of renal 
denervation for resistant hypertension. N Engl J Med. 2014;370:1393–
1401.DOI: 10.1056/NEJMo a1402670.
 22. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, 
Tsioufis K, Pocock S, Konstantinidis D, Choi JW, et al. Efficacy of cath-
eter-based renal denervation in the absence of antihypertensive med-
ications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, 
sham-controlled trial. Lancet. 2020;395:1444–1451.DOI: 10.1016/
S0140 -6736(20)30554 -7.
 23. A placebo-controlled trial of percutaneous coronary intervention 
for the relief of stable angina. ClinicalTrials.gov. 2018. Available at: 
https://clini caltr ials.gov/ct2/show/study/ NCT03 74205 0?term=ORBIT 













 http://ahajournals.org by on January 28, 2021
Table S1. Logistic (Proportional Odds) Ordinal Regression Model. 
orm(formula = outcome_anginafree_post ~ outcome_anginafree_pre + 
Number_AA_Tolerated * pci_or_placebo, data = d_pr) 
 
 β S.E. Wald Z Pr(>|Z|) 
Intercept  -1.1120  0.6564 -1.69 0.0902 
outcome_anginafree_pre   1.8191  0.4459 4.08 <0.0001 
Number_AA_Tolerated   0.2864  0.2108 1.36 0.1742 
pci_or_placebo=Placebo  -0.3281  1.1950 -0.27 0.7837 
Number_AA_Tolerated × 
pci_or_placebo=Placebo 
 -0.2176  0.3693 -0.59 0.5558 
 
Wald Statistics for outcome_anginafree_post 
 χ2 d.f. P 




1.90 2 0.3871 




9.57 2 0.0083 





0.35 1 0.5558 











Obs 192 LR χ2 27.78 R2 0.182 ρ 0.376 
FALSE 114 d.f. 4 g 0.914 
 
TRUE 78 Pr(>χ2) <0.0001 gr 2.493 
 
Distinct Y 2 Score χ2 26.80 |Pr(Y ≥ median)-½| 
0.177 
 
Y0.5 1 Pr(>χ2) <0.0001 
  
max |∂log L/∂β| 
0.0001 
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Table S2. Physician Assessed Severity of Angina. 
  PCI n(%) Placebo n(%) 
Enrolment Class n=105 n=95 
CCS 0 0 (0) 0 (0) 
 1 2 (1.9) 3 (3.2) 
 2 64 (61.0) 54 (56.8) 
 3 39 (37.1) 38 (40.0) 
Pre-randomization  n=105 n=95 
CCS 0 9 (8.6) 13 (13.7) 
 1 15 (14.3) 10 (10.5) 
 2 56 (53.3) 41 (43.2) 
 3 25 (23.8) 31 (32.6) 
Follow up  n=105 n=91 
CCS 0 41 (39.0) 26 (28.6) 
 1 14 (13.3) 18 (19.8) 
 2 37 (35.2) 31 (34.1) 
 3 13 (12.4) 15 (16.5) 
 4 0 (0) 1 (1.1) 
CCS = Canadian Cardiovascular Society 
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Table S3. Seattle Angina Questionnaire Frequency of Angina. 
 
  PCI n(%) Placebo n(%) 
Enrolment  n=103 n=92 
Frequency of angina >4 x /day 3 (2.9) 7 (7.6) 
 1-3 x /day 29 (28.2) 20 (21.7) 
 ≥3x / week but not every day 23 (22.3) 21 (22.8) 
 1-2 x / week 17 (16.5) 13 (14.1) 
 <1x /week 18 (17.5) 17 (18.5) 
 None in the past 4 weeks 13 (12.6) 14 (15.2) 
Pre-randomization  n=104 n=94 
Frequency of angina >4 x /day 2 (1.9) 4 (4.3) 
 1-3 x /day 19 (18.3) 18 (19.2) 
 ≥3x / week but not every day 15 (14.4) 17 (18.1) 
 1-2 x / week 25 (24.0) 18 (19.1) 
 <1x /week 28 (26.9) 18 (19.1) 
 None in the past 4 weeks 15 (14.4) 19 (20.2) 
Follow up   n=103 n=91 
Frequency of angina >4 x /day 2 (1.9) 4 (4.4) 
 1-3 x /day 7 (6.8) 8 (8.8) 
 ≥3x / week but not every day 13 (12.6) 12 (13.2) 
 1-2 x / week 14 (13.6) 21 (23.1) 
 <1x /week 16 (15.5) 18 (19.8) 
 None in the past 4 weeks 51 (49.5) 28 (30.8) 
PCI = percutaneous coronary intervention  
These were the answers provided by the patients to the following written question from the 
Seattle Angina Questionnaire: “Over the past 4 weeks, how many times have you had chest 
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Table S4. The blood pressure and heart rate data from the ORBITA trial, at 
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Figure S1. The percentage of patients on 0 to 5 antianginal drugs each week 
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Figure S2. Regression analysis, showing no impact of the number of 
prescribed anti-anginal therapies on the log odds of improvement in CCS class 
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Figure S3. Regression analysis, showing no impact of the number of 
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Figure S4. Regression analysis, showing no impact of the number of 
prescribed anti-anginal therapies on log odds SAQ angina frequency post 
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